26 March,2018 02:22 PM IST | Washington DC | ANI
Representational Picture
Smoking in patients with heart attack was reduced significantly with the drug varenicline, according to a study.
Patients who smoke after an acute coronary syndrome, including a heart attack (myocardial infarction) or unstable angina (reduced blood flow to the heart) are at increased risk of another attack and death if they do not quit.
Researchers from Canada looked at the efficacy of varenicline in patients with acute coronary syndrome to determine whether it would increase smoking abstinence.
ALSO READ
Mumbai doctors treat 33-year-old woman suffering from rare esophageal disorder
Diwali 2024: Mumbai doctors warn of alarming health risks from noise pollution
Breast cancer in men: Stigma delaying timely diagnoses and treatment
Prolonged exposure to arsenic in drinking water may up heart disease risk
Delhi air pollution: Doctors report 30 per cent rise in asthma, COPD cases
The randomized controlled trial included 302 patients at centres in Canada and the US who had been admitted to hospital for acute coronary syndrome, were motivated to quit smoking and who smoked at least 10 cigarettes a day for the previous year. Patients received smoking cessation counselling as well as either varenicline or a placebo control for 12 weeks. Most participants had moderate to severe nicotine dependency.
Varenicline has been shown to be efficacious in stopping smoking in patients with heart attack within the first 6 months, but its longer term efficacy was not previously known.
About 40% of participants who received varenicline were not smoking at one year, compared with 29% in the placebo group. Reductions in daily cigarette smoking of at least 50% were also higher in the varenicline group (57.8%) compared with the placebo group (49.7%). Rates of adverse events were similar in both groups.
"This suggests that varenicline is safe for use in these patients," writes Dr. Mark Eisenberg, Jewish General Hospital and McGill University, Montreal, Quebec, with coauthors. "However, new strategies for smoking cessation are still needed, given that 60% of smokers who received treatment with varenicline returned to smoking by one year after their acute coronary syndrome."
The authors note that if varenicline was used as routine treatment in smokers after heart attack, it would reduce smoking in this group by about 10%.
The findings have been published in CMAJ (Canadian Medical Association Journal).
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever